Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by One Wealth Capital Management LLC

One Wealth Capital Management LLC decreased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 88.7% in the 3rd quarter, Holdings Channel reports. The firm owned 443 shares of the pharmaceutical company’s stock after selling 3,473 shares during the period. One Wealth Capital Management LLC’s holdings in Vertex Pharmaceuticals were worth $232,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Evergreen Capital Management LLC increased its holdings in shares of Vertex Pharmaceuticals by 0.8% in the 3rd quarter. Evergreen Capital Management LLC now owns 4,257 shares of the pharmaceutical company’s stock worth $2,226,000 after buying an additional 35 shares during the last quarter. Gibbs Wealth Management raised its position in shares of Vertex Pharmaceuticals by 10.8% during the 3rd quarter. Gibbs Wealth Management now owns 6,074 shares of the pharmaceutical company’s stock valued at $3,176,000 after buying an additional 592 shares in the last quarter. Lantern Wealth Advisors LLC raised its position in shares of Vertex Pharmaceuticals by 8.0% during the 3rd quarter. Lantern Wealth Advisors LLC now owns 1,350 shares of the pharmaceutical company’s stock valued at $706,000 after buying an additional 100 shares in the last quarter. Lighthouse Financial LLC lifted its holdings in shares of Vertex Pharmaceuticals by 52.1% during the 3rd quarter. Lighthouse Financial LLC now owns 9,910 shares of the pharmaceutical company’s stock worth $5,181,000 after acquiring an additional 3,395 shares during the last quarter. Finally, Fifth Third Wealth Advisors LLC lifted its holdings in shares of Vertex Pharmaceuticals by 3.4% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 1,911 shares of the pharmaceutical company’s stock worth $999,000 after acquiring an additional 62 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors.

Vertex Pharmaceuticals Stock Performance

VRTX stock opened at $523.93 on Friday. The company has a market capitalization of $132.97 billion, a PE ratio of 30.50, a price-to-earnings-growth ratio of 2.51 and a beta of 0.28. Vertex Pharmaceuticals Incorporated has a one year low of $403.16 and a one year high of $560.25. The company’s 50 day moving average price is $523.52 and its two-hundred day moving average price is $483.25.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, August 3rd. The pharmaceutical company reported $4.73 earnings per share for the quarter, missing analysts’ consensus estimates of $4.74 by ($0.01). Vertex Pharmaceuticals had a return on equity of 23.09% and a net margin of 35.00%. The business had revenue of $3.33 billion during the quarter, compared to the consensus estimate of $3.23 billion. During the same quarter in the previous year, the firm posted $4.52 earnings per share. The company’s revenue was up 12.5% compared to the same quarter last year. On average, research analysts predict that Vertex Pharmaceuticals Incorporated will post 16.74 EPS for the current year.

Wall Street Analyst Weigh In

VRTX has been the subject of several research reports. Canaccord Genuity Group upped their target price on shares of Vertex Pharmaceuticals from $436.00 to $442.00 and gave the stock a “hold” rating in a research report on Tuesday, August 4th. Leerink Partners began coverage on Vertex Pharmaceuticals in a research report on Monday, September 21st. They set an “outperform” rating and a $594.00 price target on the stock. Jefferies Financial Group raised their price target on Vertex Pharmaceuticals from $633.00 to $640.00 and gave the company a “buy” rating in a research report on Wednesday, September 23rd. Truist Financial lifted their price target on Vertex Pharmaceuticals from $560.00 to $565.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Finally, Stifel Nicolaus set a $500.00 price objective on Vertex Pharmaceuticals and gave the stock a “hold” rating in a report on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $579.81.

Trending Headlines about Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Povetacicept delivered positive Phase 3 results. Vertex said the RAINIER trial met all key endpoints in IgA nephropathy, an immune-mediated kidney disease. The results were published in the New England Journal of Medicine and presented at the American Society of Nephrology meeting, supporting the drug’s potential to become an important commercial product. Vertex Pharmaceuticals Posts Positive Phase 3 Results for Povetacicept
• Positive Sentiment: Vertex plans to seek FDA accelerated approval for povetacicept in IgA nephropathy. Regulatory progress could bring a new revenue source closer and reduce the company’s reliance on its cystic fibrosis franchise. Phase 3 RAINIER Results for Povetacicept
• Positive Sentiment: Pipeline diversification is becoming more credible. About 96% of Vertex’s product sales currently come from cystic fibrosis treatments, but povetacicept and inaxaplin could expand the company into kidney disease. Inaxaplin is viewed as a potential blockbuster, adding longer-term growth optionality. Vertex Pharmaceuticals Pipeline Diversification
• Neutral Sentiment: Vertex highlighted its broader kidney-disease research program at ASN Kidney Week 2026, but the presentations do not appear to add a major new financial forecast beyond the povetacicept results. Vertex ASN Kidney Week 2026 Transcript
• Negative Sentiment: Erste Group Bank slightly reduced its EPS forecasts. The firm cut its FY2026 estimate to $16.65 from $16.68 and its FY2027 estimate to $18.97 from $19.09. While the reductions are small, they may weigh on sentiment and highlight near-term earnings uncertainty. Vertex Pharmaceuticals Analyst Estimates

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.

Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene.